Volume 21, Number 1—January 2015
Workshop on Use of Intravenous Immunoglobulin in Hand, Foot and Mouth Disease in Southeast Asia
|Absolute risk of progression, IVIg group||Absolute risk increase for placebo group compared with IVIg
*Sample sizes are total sample sizes (i.e., for both groups combined) but do not account for loss-to-follow-up or increases in sample size that would be required if formal interim analyses with stopping boundaries are planned. IVIg, intravenous immunoglobulin.